MedTrace Logo

A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis

NCT02780388 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2024-12-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether VIB4920 (formerly MEDI4920) is safe and well tolerated in participants with adult-onset rheumatoid arthritis (RA).

Conditions

  • Adult Onset Rheumatoid Arthritis

Interventions

DRUG

VIB4920

Participants will receive a single IV dose of VIB4920 Q2W from Day 1 up to 12 weeks.

OTHER

Placebo

Participants will receive a single IV dose of placebo matched to VIB4920 Q2W from Day 1 up to 12 weeks.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-12
Primary Completion
2018-05-21
Completion
2018-08-09
FDA Drug
Yes

Countries

  • United States
  • Poland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02780388 on ClinicalTrials.gov